Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| LYMNHL0040-BMT212 | Other Identifier | OnCore | |
| 96940 | Other Identifier | Stanford University Alternate IRB Approval Number | |
| NCI-2011-00136 | Other Identifier | NCI Trial ID |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
Not provided
Not provided
Not provided
Not provided
Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally considered incurable with current therapy. Participants will receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. This vaccination may prolong the time which patients will stay in remission from their disease.
Study treatment is a complex set of steps of research procedures and regular medical care. By using a participant's cancer cells as an immungen, the study hopes to improve freedom from molecular residual disease (MRD).
PRIMARY OBJECTIVE Freedom from molecular residual disease at 1-year post-autologous transplant.
SECONDARY OBJECTIVE Time To Clinical Progression (TTP)
This study has 2 research agents, PF-03152676 and CpG-MCL Vaccine.
PF-03152676 is a synthetic DNA molecule, 24 nucleotides in length with a nuclease-resistant phosphorothioate backbone. It is an immunostimulatory, single-stranded oligodeoxynucleotide (oligo-DNA) containing unmethylated cytosine and guanine (CpG) motifs and synthesized with a nuclease-resistant phosphorothioate backbone. PF-03512676 acts as an agonist of human Toll-like receptor 9, leading to activation of antigen-presenting cells and a cascade of anti-tumor immune reactions.
CpG-MCL Vaccine is the primary study agent. It is prepared by dissociating a participant's harvested tumor cells into a single-cell suspension, and culturing them with PF-03152676 for 72 hours at 37 degrees C, 5% CO2 to allow for up-regulation of antigen-presenting and co-stimulatory molecules, then irradiated to 200 Gy to destroy any remaining cancer propagating ability.
The study procedure is summarized as 12 steps, listed below.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CpG-MCL Vaccine | Experimental | An autologous anti-tumor vaccine. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CpG-MCL vaccine | Biological | CpG-MCL vaccine is a vaccine prepared by co-culturing cells from the participant's mantle cell lymphoma suspension with 3 mcg/mL PF-3512676, then irradiated to 200 Gy. 1 x 10e8 CpG-MCL cells will be given as a subcutaneous injection. |
| Measure | Description | Time Frame |
|---|---|---|
| Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) | Molecular residual disease (MRD) is defined as detection in blood samples by the ClonoSEQ test of the (11;14) (q13;q32) gene translocation. It is considered positive if a tumor-specific VDJ sequence is detected in the peripheral blood cells by Ig-HTS at a frequency of greater or equal to 1 molecule per 10,000 input leukocyte equivalents of DNA within 1 year post-autologous stem cell transplant (ASCT). The outcome will be reported as number and percent of participants that maintain MRD-negative status (ie, 1-year freedom from MRD). This outcome is reported as a number without dispersion. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Time-to-progression (TTP) | Time-to-progression (TTP) is measured from the time of autologous stem cell transplantation (ASCT) until the cancer progresses or relapses. Progression is assessed based on CT imaging per the Cheson Criteria (2008). Progression per the Cheson Criteria is defined as having occurred when the sum of tumor lesion dimensions is ≥ 150% of the baseline value. The outcome is reported as the median with 95% confidence interval, as determined by Kaplan-Meier analysis and log-rank test. |
Not provided
INCLUSION CRITERIA
EXCLUSION CRITERIA
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ronald Levy, MD | Stanford University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University Medical Center | Stanford | California | 94305 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 18812472 | Background | Brody JD, Goldstein MJ, Czerwinski DK, Levy R. Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood. 2009 Jan 1;113(1):85-94. doi: 10.1182/blood-2008-05-155457. Epub 2008 Sep 23. | |
| Result | Czerwinski DK, Brody J, Kohrt HE, et al. "Immunotransplant Expands Vaccine Induced Memory T cell Responses In Patients With Mantle Cell Lymphoma." Blood. 2013;122(21)1816. | ||
| Result | Chu MP, Brody J, Kohrt HE, et al. "Phase I/II Clinical Trial of CpG Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis Blood." Blood. 2015;126(23) | ||
| Result | Frank MJ, Khodadoust M, Chu M, et al. "Phase I/II Clinical trial of an activated whole tumor cell vaccine followed by transfer of immune T cells in patients with Mantle Cell Lymphoma." Hematological Oncology). 7 June 2017, https://doi.org/10.1002/hon.2438_72. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Some participants started study procedures, but did not receive the intended study treatment.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | CpG-MCL Vaccine | An autologous anti-tumor vaccine. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Completed Pre-CpG-MCL Vaccine Procedures |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Apr 4, 2016 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| PF-3512676 | Biological | PF-03152676 is a synthetic immunostimulatory, single-stranded oligodeoxynucleotide (oligo-DNA) moledule containing unmethylated cytosine and guanine (CpG) motifs. PF-03512676 acts as an agonist of human Toll-like receptor 9, leading to activation of antigen-presenting cells and a cascade of antitumor immune reactions. |
|
|
| Vaccine-primed T-cells | Procedure | Vaccine primed T-cells are the post-vaccination leukapheresis harvest of peripheral blood mononuclear cells. Each collection is approx 1 x 10e10 CD3+ T-cells. |
|
| Autologous hematopoietic stem cell transplant (HSCT) | Procedure | Regular medical procedure |
|
|
| Rituximab | Drug | 375 mg/m² by infusion |
|
|
| Standard induction chemotherapy | Drug | Patient-specific, regular medical care treatment as determined by treating oncologist |
|
| Cyclophosphamide | Drug | Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC) |
|
|
| Filgrastim | Drug | Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC) |
|
|
| 7.7 years |
| Overall Survival (OS) | Overall survival (OS) rate is reported as number and percentage of participants remaining alive the date of transplant through each year, up to 5 years (reported as a number without dispersion). | After 1, 2, 3, 4, and 5 years |
| Detection of Tumor-specific CD8-positve Memory T-cells Before and After Vaccination | Anti-tumor T-cell immune responses were evaluated by an in vitro evocative test on their peripheral blood mononuclear cell (PBMCs) before and after vaccination, as assessed by measurement of intracellular cytokines and/or intracellular perforin/granzyme in CD8+ T-cells, and/or CD137 induction on CD4+ T-cells. PBMCs were co-cultured with CpG-activated autologous MCL tumor cells and evaluated for tumor-specific immune responses as measured by CD137 expression on their T cells. The outcome is reported as the number of participants for whom tumor-specific memory CD8 cells were detected at baseline and after vaccination and transplant (numbers without dispersion). | Baseline and after vaccination and transplant, approximately 5 years |
| Detection of Tumor-specific CD4-positve T-cells Before and After Vaccination | Anti-tumor T-cell immune responses were evaluated by an in vitro evocative test on their peripheral blood mononuclear cell (PBMCs) before and after vaccination, as assessed by measurement of intracellular cytokines and/or intracellular perforin/granzyme in CD8+ T-cells, and/or CD137 induction on CD4+ T-cells. PBMCs were co-cultured with CpG-activated autologous MCL tumor cells and evaluated for tumor-specific immune responses as measured by CD137 expression on their T cells. The outcome is reported as the number of participants for whom tumor-specific memory CD4 cells were detected at baseline and after transplant (numbers without dispersion). | Baseline and after vaccination and transplant, approximately 5 years |
| 32558897 | Derived | Frank MJ, Khodadoust MS, Czerwinski DK, Haabeth OAW, Chu MP, Miklos DB, Advani RH, Alizadeh AA, Gupta NK, Maeda LS, Reddy SA, Laport GG, Meyer EH, Negrin RS, Rezvani AR, Weng WK, Sheehan K, Faham M, Okada A, Moore AH, Phillips DL, Wapnir IL, Brody JD, Levy R. Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. J Exp Med. 2020 Sep 7;217(9):e20191712. doi: 10.1084/jem.20191712. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
| Treatment With CpG-MCL Vaccine |
|
|
Includes all participants that started study procedures. Prospective participants that consented but did not receive any research procedures are not included.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | CpG-MCL Vaccine | An autologous anti-tumor vaccine. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) | Molecular residual disease (MRD) is defined as detection in blood samples by the ClonoSEQ test of the (11;14) (q13;q32) gene translocation. It is considered positive if a tumor-specific VDJ sequence is detected in the peripheral blood cells by Ig-HTS at a frequency of greater or equal to 1 molecule per 10,000 input leukocyte equivalents of DNA within 1 year post-autologous stem cell transplant (ASCT). The outcome will be reported as number and percent of participants that maintain MRD-negative status (ie, 1-year freedom from MRD). This outcome is reported as a number without dispersion. | Only participants for which molecular residual disease (MRD) disease status assessments were available are included. | Posted | Count of Participants | Participants | 12 months |
|
|
| ||||||||||||||||||||||||||
| Secondary | Time-to-progression (TTP) | Time-to-progression (TTP) is measured from the time of autologous stem cell transplantation (ASCT) until the cancer progresses or relapses. Progression is assessed based on CT imaging per the Cheson Criteria (2008). Progression per the Cheson Criteria is defined as having occurred when the sum of tumor lesion dimensions is ≥ 150% of the baseline value. The outcome is reported as the median with 95% confidence interval, as determined by Kaplan-Meier analysis and log-rank test. | Posted | Median | 95% Confidence Interval | years | 7.7 years |
| ||||||||||||||||||||||||||||
| Secondary | Overall Survival (OS) | Overall survival (OS) rate is reported as number and percentage of participants remaining alive the date of transplant through each year, up to 5 years (reported as a number without dispersion). | Only participants that received the CpG-MCL Vaccine are included. | Posted | Count of Participants | Participants | After 1, 2, 3, 4, and 5 years |
|
| |||||||||||||||||||||||||||
| Secondary | Detection of Tumor-specific CD8-positve Memory T-cells Before and After Vaccination | Anti-tumor T-cell immune responses were evaluated by an in vitro evocative test on their peripheral blood mononuclear cell (PBMCs) before and after vaccination, as assessed by measurement of intracellular cytokines and/or intracellular perforin/granzyme in CD8+ T-cells, and/or CD137 induction on CD4+ T-cells. PBMCs were co-cultured with CpG-activated autologous MCL tumor cells and evaluated for tumor-specific immune responses as measured by CD137 expression on their T cells. The outcome is reported as the number of participants for whom tumor-specific memory CD8 cells were detected at baseline and after vaccination and transplant (numbers without dispersion). | Only participants for which both baseline and post-transplant assessments were available are included. | Posted | Count of Participants | Participants | Baseline and after vaccination and transplant, approximately 5 years |
| ||||||||||||||||||||||||||||
| Secondary | Detection of Tumor-specific CD4-positve T-cells Before and After Vaccination | Anti-tumor T-cell immune responses were evaluated by an in vitro evocative test on their peripheral blood mononuclear cell (PBMCs) before and after vaccination, as assessed by measurement of intracellular cytokines and/or intracellular perforin/granzyme in CD8+ T-cells, and/or CD137 induction on CD4+ T-cells. PBMCs were co-cultured with CpG-activated autologous MCL tumor cells and evaluated for tumor-specific immune responses as measured by CD137 expression on their T cells. The outcome is reported as the number of participants for whom tumor-specific memory CD4 cells were detected at baseline and after transplant (numbers without dispersion). | Only participants for which both baseline and post-transplant assessments were available are included. | Posted | Count of Participants | Participants | Baseline and after vaccination and transplant, approximately 5 years |
|
3 months
The study has 2 stages, ie, procedures preceding vaccine administration + the vaccine treatment period.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | CpG-MCL Vaccine | An autologous anti-tumor vaccine. | 19 | 59 | 31 | 48 | 48 | 48 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hemorrhage, CNS, Intracranial hemorrhage | Nervous system disorders | CTCAE v3.0 | Systematic Assessment |
| |
| Thrombosis/embolism | Vascular disorders | CTCAE v3.0 | Systematic Assessment |
| |
| Adult Respiratory Distress Syndrome (ARDS) | Respiratory, thoracic and mediastinal disorders | CTCAE v3.0 | Systematic Assessment |
| |
| Blood and lymphatic system disorders - Other, Graft failure | Blood and lymphatic system disorders | CTCAE v3.0 | Systematic Assessment |
| |
| Infection, dental abscess | Infections and infestations | CTCAE v3.0 | Systematic Assessment |
| |
| Leukocytes (total WBC) | Investigations | CTCAE v3.0 | Systematic Assessment |
| |
| Febrile Neutropenia | Blood and lymphatic system disorders | CTCAE v3.0 | Systematic Assessment |
| |
| Pneumonitis | Respiratory, thoracic and mediastinal disorders | CTCAE v3.0 | Systematic Assessment |
| |
| Supraventricular and nodal arrhythmia | Vascular disorders | CTCAE v3.0 | Systematic Assessment |
| |
| Death NOS | General disorders | CTCAE v3.0 | Systematic Assessment |
| |
| Neutrophils/granulocytes (ANC/AGC) | Blood and lymphatic system disorders | CTCAE v3.0 | Systematic Assessment |
| |
| Platelets | Blood and lymphatic system disorders | CTCAE v3.0 | Systematic Assessment |
| |
| Myositis | Musculoskeletal and connective tissue disorders | CTCAE v3.0 | Systematic Assessment |
| |
| Death Disease progression | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | CTCAE v3.0 | Systematic Assessment |
| |
| Burn | Skin and subcutaneous tissue disorders | CTCAE v3.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pain Joint (Arthalgia) | Musculoskeletal and connective tissue disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Phantom sensations (sensitivity/crawly feeling on skin) | Psychiatric disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Abdomen NOS | Gastrointestinal disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Anorexia | Gastrointestinal disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Hip pain | Musculoskeletal and connective tissue disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Diarrhea | Gastrointestinal disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Distension/bloating Abdominal (Gas/indigestion) | Gastrointestinal disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Fatigue | General disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Fever | General disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Febrile neutropenia | Blood and lymphatic system disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Flu-like syndrome: General | General disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Head/Headache | Nervous system disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Heartburn/dyspepsia | Gastrointestinal disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Hyperpigmentation | Skin and subcutaneous tissue disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Imsomnia | Nervous system disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Induration | Skin and subcutaneous tissue disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Metapneumovirus | Infections and infestations | CTCAEv 3.0 | Systematic Assessment |
| |
| Injection site reaction/extravasation changes: Erythema | General disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Injection site reaction/extravasation changes: Pain | General disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Injection site reaction/extravasation changes: Swelling | General disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Injection site reaction/extravasation changes: Warmth | General disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Joint Function | Musculoskeletal and connective tissue disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Leukocytes count low | Blood and lymphatic system disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Lymphocytes count low | Blood and lymphatic system disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Mucositis/Stomatitis | Gastrointestinal disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| nasal congestion | Respiratory, thoracic and mediastinal disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Neutrophils/granulocytes count low | Investigations | CTCAEv 3.0 | Systematic Assessment |
| |
| Other: Granuloma | Skin and subcutaneous tissue disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Other: thinning/fragile skin | Skin and subcutaneous tissue disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Platelets count low | Blood and lymphatic system disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Pneumonitis | Respiratory, thoracic and mediastinal disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Pruritis/Itching | Skin and subcutaneous tissue disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Rash/Desquamation | Skin and subcutaneous tissue disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Rigors/Chills | General disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Syncope | Nervous system disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Thrombosis | Vascular disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Voice changes/dysarthia | Respiratory, thoracic and mediastinal disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | CTCAEv 3.0 | Systematic Assessment |
| |
| Weight Loss | General disorders | CTCAEv 3.0 | Systematic Assessment |
|
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Ronald Levy | Stanford University | 650-725-6452 | levy@stanford.edu |
| Jan 8, 2020 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D020522 | Lymphoma, Mantle-Cell |
| ID | Term |
|---|---|
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C483020 | ProMune |
| D014180 | Transplantation |
| D000069283 | Rituximab |
| D003520 | Cyclophosphamide |
| D000069585 | Filgrastim |
| D016179 | Granulocyte Colony-Stimulating Factor |
| ID | Term |
|---|---|
| D013514 | Surgical Procedures, Operative |
| D058846 | Antibodies, Monoclonal, Murine-Derived |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D010752 | Phosphoramide Mustards |
| D009588 | Nitrogen Mustard Compounds |
| D009150 | Mustard Compounds |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D063088 | Phosphoramides |
| D009943 | Organophosphorus Compounds |
| D003115 | Colony-Stimulating Factors |
| D006023 | Glycoproteins |
| D006001 | Glycoconjugates |
| D002241 | Carbohydrates |
| D016298 | Hematopoietic Cell Growth Factors |
| D016207 | Cytokines |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D010455 | Peptides |
| D001685 | Biological Factors |
Not provided
Not provided
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Units | Counts |
|---|
| Participants |
|
|
| Participants |
|
|
|
|
|
|